Truist Securities analyst Terry Tillman downgrades Five9 (NASDAQ:FIVN) from Buy to Hold and lowers the price target from $225 to $212.
SVB Leerink Downgrades Vertex Pharmaceuticals to Underperform, Lowers Price Target to $170
SVB Leerink analyst Geoffrey Porges downgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Market Perform to Underperform and lowers the price target from $200 to $170.